You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,891,219


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,891,219
Title:Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive
Abstract: The invention provides prognostic methods for evaluating the severity of NMO and NMO-associated diseases as well as methods of treating NMO and NMO-associated diseases.
Inventor(s): Lennon; Vanda A. (Rochester, MN), Hinson; Shannon (Rochester, MN), Pittock; Sean J. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:12/573,942
Patent Claims:1. A method of treating an individual that has neuromyelitis optica (NMO), comprising: identifying an individual that is serologically positive for aquaporin-4 (AQP4)-IgG autoantibody; and administering eculizumab to the individual.

2. The method of claim 1, wherein eculizumab is administered intravenously.

3. A method of treating an individual that has NMO, comprising the steps of: identifying an individual that is serologically positive for aquaporin-4 (AQP4)-IgG autoantibody; determining the complement-activating capacity of AQP4-IgG autoantibody in a biological sample from the individual; and administering an effective amount of eculizumab to the individual.

4. The method of claim 3, wherein the eculizumab is administered intravenously.

5. A method for treating neuromyelitis optica (NMO), wherein said method comprises administering eculizumab to an individual identified as being serologically positive for an aquaporin-4 (AQP4)-IgG autoantibody.

6. The method of claim 5, wherein said eculizumab is administered intravenously to said individual.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.